Cross-linking agents and associated methods

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 11065275
APP PUB NO 20190083529A1
SERIAL NO

16083865

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

An ophthalmic composition or dosage form can include a therapeutically effective amount of a cross-linking agent and a pharmaceutically acceptable carrier. The composition or dosage form can be used to treat an ophthalmic condition by administering a therapeutically effective amount of the composition to an eye of a subject during a treatment period.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • UNIVERSITY OF UTAH RESEARCH FOUNDATION

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Ambati, Balamurali K Sandy, US 23 166
Muddana, Santosh Salt Lake City, US 3 7
Uehara, Hironori Salt Lake City, US 8 19

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jan 20, 2029
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jan 20, 2033
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00